Invion Ltd News

Invion Partners With Hanlim Pharma for Glioblastoma Treatment

Life-sciences company Invion (ASX:IVX) entered into a collaboration agreement with South Korean pharmaceutical group Hanlim Pharma (KRX:128940) to develop the Photosoft lead candidate, INV043, for the

MT NewswiresMay 7 20:31

Invion Ltd. Advances in Clinical Trials and HPV Research

TipRanksApr 30 04:37

Invion's Anti-Cancer Drug Logs Postive Preclinical Trial Results

Invion (ASX:IVX) said preclinical studies of its INV043 anti-cancer medication show that the drug, when applied topically in combination with an immune checkpoint inhibitor (ICI), resulted in nearly 8

MT NewswiresMar 5 05:11

Invion Signs Collaboration Agreement With Dr. I&B Co for HPV Treatment; Shares Up 25%

Invion (ASX:IVX) entered into a collaboration agreement with South Korean company, Dr. I&B Co. to develop Photosoft for the treatment of the human papilloma virus, according to a Friday filing. Under

MT NewswiresFeb 22 21:04

Invion Nears Clinical Trial of Cancer Photodynamic Therapy With Drug Substance Production

Invion (ASX:IVX) said it made a significant step towards initiating the clinical trials of INV043 following the "successful" production of the said drug substance by partner IDT Australia (ASX:IDT). W

MT NewswiresNov 21, 2023 07:16

Invion (ASX:IVX) Is In A Good Position To Deliver On Growth Plans

Yahoo FinanceOct 23, 2023 17:48

Invion Grants RMW Cho Group Right to Distribute Cancer Treatment Products in South Korea

Invion (ASX:IVX) granted RMW Cho Group a license and the right to distribute its cancer treatment technology, Photosoft, and other cancer indications in South Korea. As part of an agreement between th

MT NewswiresSep 26, 2023 03:43